Global Regenerative Medicine Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, Japan, China - Size and Forecast 2024-2028

Published: Oct 2023 Pages: 178 SKU: IRTNTR41171

Regenerative Medicine Market Size 2024-2028

The regenerative medicine market is projected to reach a value of USD 70.11 billion, accelerating at a CAGR of 23.31% between 2023 and 2028. The rising incidence of chronic illnesses is driving significant growth across multiple markets. With a substantial portion of the global population affected by these enduring health conditions, there's a growing need for pioneering therapies and solutions to combat these ailments effectively. As chronic diseases persist as a prevalent concern worldwide, the demand for innovative treatments and interventions continues to surge. This escalating need underscores the critical role played by various industries in developing and providing cutting-edge solutions to address the complexities of chronic illnesses. Stakeholders across healthcare sectors are compelled to innovate, collaborate, and invest in research and development efforts to meet the evolving healthcare needs of individuals grappling with chronic conditions. In essence, the relentless prevalence of chronic diseases serves as a compelling catalyst propelling advancements and growth within diverse market segments.

Market Overview

For More Highlights About this market Report, Download Free Sample in a Minute 

Market Segmentation

The market is a dynamic landscape encompassing various domains, such as blood cancers, rare diseases, and chronic genetic disorders. Notably, advancements in personalized medicine, gene therapy, and CRISPR therapy are driving transformative changes. Companies like Metcela Inc, Integra LifeSciences, and ACell, Inc are pivotal players in this sector, leveraging their R&D capabilities to develop innovative cellular therapies and tissue engineering solutions. Strategic initiatives such as mergers, research collaborations, and partnerships are fostering the development of groundbreaking treatments like CAR-T treatment and gene therapy. Moreover, the focus on platelet-rich plasma and advancements in orthopedics and wound care underscore the market's potential in oncology and tissue regeneration. This market segmentation showcases a thriving ecosystem propelled by healthcare expenditure, government organizations' support, and a robust pipeline of innovative pipeline candidates across various therapeutic areas.

The market is segmented into application, technology, and geography. The oncology sub segment under the application segment generated the largest revenue in 2018. Key regions boosting the market growth include North America, Europe, Asia, and Rest of World (ROW).

By Application 

The market share growth by the oncology segment will be significant during the forecast period. The global regenerative medicines market is poised for significant growth in the oncology application segment during the forecast period. Government data from organizations such as the World Health Organization (WHO) and the European Medicines Agency (EMA) indicate that a number of variables contribute to this trend.

Get a glance at the market contribution of various segments Download the PDF Sample

The oncology segment was the largest and was valued at USD 5.58 billion in 2018. Regenerative medicine offers cutting-edge cellular therapies such as CAR-T cell therapy and stem cell-based therapeutics. These discoveries have the potential to treat a number of malignancies, including leukemia and lymphoma. Also,  Governments are supporting the development of regenerative medicine through regulatory assistance. The market in focus is expanding due to EMA rules on advanced treatment medical products (ATMPs).  Governments are supporting the development of regenerative medicine through regulatory assistance. The market in focus is expanding due to EMA rules on advanced treatment medical products (ATMPs). Such factors are expected to fuel the growth of the segment, which in turn drives the market growth during the forecast period. 

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 48% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In North America, approximately 510 regenerative medicine companies operate, with leading players such as Integra LifeSciences, MiMedx, Organogenesis, and Zimmer Biomet Holdings Inc. spearheading regional market growth. These entities are actively introducing novel products and restructuring sales strategies to enhance their market presence. Various factors, including the rising incidence of chronic and acute diseases, a rapidly aging populace, heightened awareness of regenerative therapies, widespread acceptance of cell and tissue-based therapies and gene therapy, the substantial presence of tissue banks, and a concerted emphasis on regenerative medicine, collectively drive market expansion across the region. In Canada, robust demand for superior medical technologies, escalating healthcare expenditure, and institutional backing, notably from the Centre for Commercialization of Regenerative Medicine, are fostering the adoption of regenerative medicine and bolstering market growth.

Market Dynamics

The landscape of healthcare is rapidly evolving with advancements in personalized medicine, gene therapy, and CRISPR therapy revolutionizing treatments for blood cancers, rare diseases, and chronic genetic disorders. Innovative pipeline candidates in oncology, cellular therapies, and gene therapy hold promise for improved patient outcomes. As healthcare expenditure rises, research grants fuel R&D capabilities, driving discoveries like the TRIM72 protein's role in vasculature and skeletal muscles. Companies like Integra LifeSciences lead in orthopedics and wound care, while CellPoint pioneers cellular therapies like CAR-T treatment and tissue engineering. Platelet-rich plasma offers novel solutions, underscoring the dynamic intersection of science and patient care.

Major Market Driver

The rising incidence of chronic diseases is a key driver of market growth. Globally, there is a growing prevalence of conditions like heart disease, diabetes, stroke, cancer, obesity, and arthritis, posing a substantial burden on both patients and healthcare systems.

Moreover, in the US, a significant portion of the population contends with one or more chronic health conditions, with one in four adults facing two or more chronic diseases. Unhealthy lifestyle habits, including insufficient exercise, poor nutrition, and substance abuse (such as alcohol and tobacco addiction), contribute significantly to the risk factors associated with chronic diseases.

Key Market Trends

The rising significance of Chimeric Antigen Receptor T-cell (CAR-T) therapies is a notable trend influencing market growth. CAR-T therapies, a key development in the global market, demonstrate the potential of genetically modifying a patient's T-cells to target and eliminate cancer cells, particularly in hematological malignancies like leukemia and lymphoma. FDA-approved CAR-T treatments, such as Kymriah and Yescarta, have shown remarkable success in treating large B-cell lymphoma and refractory B-cell acute lymphoblastic leukemia (ALL).

Furthermore, the established precedent of regenerative medicine in other disease areas enhances the market's growth potential. The ability to engineer a patient's immune cells for personalized, targeted cancer treatments is expected to drive the global market in the forecast period.

Significant Market Challenge

The increasing complexity of regenerative medicine products poses a significant challenge to market growth. These products, including those categorized as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) for cell therapy, exhibit complexity in various aspects, such as donor and tissue sources, product characterization, mechanism of action, potency, efficacy, and safety.

Furthermore, procedures involving the extraction and manipulation of an individual's cells for regenerative medicine, notably ex vivo autologous therapies, entail intricate processes and necessitate diverse procedures and care settings. This complexity poses challenges for healthcare systems originally tailored for conventional therapies. Additionally, there exists an insufficient regulatory framework and a lack of reimbursement for such intricate therapies. Consequently, the slow adoption rate of highly complex regenerative products is expected to present a barrier to market growth in the forecast period.

Key Companies in Market

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc. - The company offers regenerative medicine solutions such as Alloderm select and Alloderm.

The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

  • Amgen Inc.
  • Baxter International Inc.
  • Becton Dickinson and Co.
  • Cook Group Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • Integra Lifesciences Corp.
  • Johnson and Johnson
  • Medtronic Plc
  • Merck and Co. Inc.
  • Mesoblast Ltd.
  • MiMedx Group Inc.
  • Novartis AG
  • Nuvasive Inc.
  • Organogenesis Holdings Inc.
  • Smith and Nephew plc
  • Thermo Fisher Scientific Inc.
  • Vericel Corp.
  • Zimmer Biomet Holdings Inc.

The market growth and forecasting analysis of companies involves both qualitative and quantitative assessments to provide clients with insights into the broader business landscape and the strengths and weaknesses of key market players. Qualitative analysis categorizes companies based on their focus as pure play, category-focused, industry-focused, or diversified. On the other hand, quantitative analysis categorizes companies according to their market position as dominant, leading, strong, tentative, or weak. This comprehensive approach aids in understanding market dynamics and assists clients in making informed decisions regarding their business strategies.

Market Analyst Overview

The market is at the forefront of medical innovation, targeting various conditions like blood cancers, rare diseases, and chronic genetic disorders. Advancements in personalized medicine and CRISPR therapy have revolutionized treatment approaches, particularly through CAR-T treatment and investigational CAR-T cell therapies. Companies like Metcela Inc are leveraging their R&D capabilities to develop biological therapies and Molecular medicines, especially for conditions like diabetes type 1 & 2 and neurodegenerative diseases such as Alzheimer’s. This market's growth is propelled by strategic acquisitions, research grants, and government organizations' initiatives, including FDA regulatory approvals and RMAT designation for breakthrough therapies.

Moreover, the focus on tissue engineering, stem cell regeneration, and cell regeneration therapy indicates a shift toward regenerative knee treatment and tissue repair and replacement. Challenges persist in orthopedic challenges and traditional surgeries, prompting interest in Nanotechnology and regenerative therapy for musculoskeletal treatments and spinal cord injuries. As regenerative medicine continues to evolve, it holds promise for addressing age-related disorders and reducing the prevalence of cancer and cancer-related deaths while advancing cardiovascular segment with cell-based therapies.

Additionally, regenerative medicine is revolutionizing healthcare by leveraging TRIM72 protein and platelet-rich plasma for tissue repair. It's gaining traction in hospitals, clinics, and academic research institutes due to its potential to replace conventional treatment approaches. With advancements like T-Charge™ and CAR-T platform, it offers hope for conditions previously untreatable. From dermatology to orthopedics, it's exploring gene-based therapy, stem cells, and tissue-based regenerative therapies to combat degenerative disorders and enhance vision in the geriatric population. Companies like BlueRock Therapeutics are leading Phase I-III trials in this promising therapeutic category.

Market Scope

Report Coverage

Details

Page number

178

Base year

2023

Historic period

 2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 23.31%

Market growth 2024-2028

USD 70.11 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

22.43

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 48%

Key countries

US, Germany, UK, Japan, and China

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Amgen Inc., Baxter International Inc., Becton Dickinson and Co., Cook Group Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Integra Lifesciences Corp., Johnson and Johnson, Medtronic Plc, Merck and Co. Inc., Mesoblast Ltd., MiMedx Group Inc., Novartis AG, Nuvasive Inc., Organogenesis Holdings Inc., Smith and Nephew plc, Thermo Fisher Scientific Inc., Vericel Corp., and Zimmer Biomet Holdings Inc.

Market dynamics

Parent market analysis, market growth analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download PDF Sample

What are the Key Data Covered in Regenerative Medicine Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the market between 2024 and 2028
  • Precise estimation of the size of the market  size and its contribution of the market in focus to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough market report analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market forecast analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. 

Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Figure 01: Executive Summary – Chart on Market Overview
    • Figure 02: Executive Summary – Data Table on Market Overview
    • Figure 03: Executive Summary – Chart on Global Market Characteristics
    • Figure 04: Executive Summary – Chart on Market by Geography
    • Figure 05: Executive Summary – Chart on Market Segmentation by Application
    • Figure 06: Executive Summary – Chart on Market Segmentation by Technology
    • Figure 07: Executive Summary – Chart on Incremental Growth
    • Figure 08: Executive Summary – Data Table on Incremental Growth
    • Figure 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Figure 10: Parent market
    • Figure 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Figure 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Figure 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Figure 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Figure 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Figure 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Figure 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global regenerative medicine market 2018 - 2022
      • Figure 18: Historic Market Size – Data Table on global regenerative medicine market 2018 - 2022 ($ billion)
    • 4.2 Application Segment Analysis 2018 - 2022
      • Figure 19: Historic Market Size – Application Segment 2018 - 2022 ($ billion)
    • 4.3 Technology Segment Analysis 2018 - 2022
      • Figure 20: Historic Market Size – Technology Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Figure 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Figure 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Figure 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Figure 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Figure 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Figure 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Figure 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Figure 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Figure 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Application

    • 6.1 Market segments
      • Figure 30: Chart on Application - Market share 2023-2028 (%)
      • Figure 31: Data Table on Application - Market share 2023-2028 (%)
    • 6.2 Comparison by Application
      • Figure 32: Chart on Comparison by Application
      • Figure 33: Data Table on Comparison by Application
    • 6.3 Oncology - Market size and forecast 2023-2028
      • Figure 34: Chart on Oncology - Market size and forecast 2023-2028 ($ billion)
      • Figure 35: Data Table on Oncology - Market size and forecast 2023-2028 ($ billion)
      • Figure 36: Chart on Oncology - Year-over-year growth 2023-2028 (%)
      • Figure 37: Data Table on Oncology - Year-over-year growth 2023-2028 (%)
    • 6.4 Musculoskeletal - Market size and forecast 2023-2028
      • Figure 38: Chart on Musculoskeletal - Market size and forecast 2023-2028 ($ billion)
      • Figure 39: Data Table on Musculoskeletal - Market size and forecast 2023-2028 ($ billion)
      • Figure 40: Chart on Musculoskeletal - Year-over-year growth 2023-2028 (%)
      • Figure 41: Data Table on Musculoskeletal - Year-over-year growth 2023-2028 (%)
    • 6.5 Dermatology - Market size and forecast 2023-2028
      • Figure 42: Chart on Dermatology - Market size and forecast 2023-2028 ($ billion)
      • Figure 43: Data Table on Dermatology - Market size and forecast 2023-2028 ($ billion)
      • Figure 44: Chart on Dermatology - Year-over-year growth 2023-2028 (%)
      • Figure 45: Data Table on Dermatology - Year-over-year growth 2023-2028 (%)
    • 6.6 Immunology and inflammation and others - Market size and forecast 2023-2028
      • Figure 46: Chart on Immunology and inflammation and others - Market size and forecast 2023-2028 ($ billion)
      • Figure 47: Data Table on Immunology and inflammation and others - Market size and forecast 2023-2028 ($ billion)
      • Figure 48: Chart on Immunology and inflammation and others - Year-over-year growth 2023-2028 (%)
      • Figure 49: Data Table on Immunology and inflammation and others - Year-over-year growth 2023-2028 (%)
    • 6.7 Market opportunity by Application
      • Figure 50: Market opportunity by Application ($ billion)
      • Figure 51: Data Table on Market opportunity by Application ($ billion)

    7 Market Segmentation by Technology

    • 7.1 Market segments
      • Figure 52: Chart on Technology - Market share 2023-2028 (%)
      • Figure 53: Data Table on Technology - Market share 2023-2028 (%)
    • 7.2 Comparison by Technology
      • Figure 54: Chart on Comparison by Technology
      • Figure 55: Data Table on Comparison by Technology
    • 7.3 Cell and tissue-based - Market size and forecast 2023-2028
      • Figure 56: Chart on Cell and tissue-based - Market size and forecast 2023-2028 ($ billion)
      • Figure 57: Data Table on Cell and tissue-based - Market size and forecast 2023-2028 ($ billion)
      • Figure 58: Chart on Cell and tissue-based - Year-over-year growth 2023-2028 (%)
      • Figure 59: Data Table on Cell and tissue-based - Year-over-year growth 2023-2028 (%)
    • 7.4 Gene therapy - Market size and forecast 2023-2028
      • Figure 60: Chart on Gene therapy - Market size and forecast 2023-2028 ($ billion)
      • Figure 61: Data Table on Gene therapy - Market size and forecast 2023-2028 ($ billion)
      • Figure 62: Chart on Gene therapy - Year-over-year growth 2023-2028 (%)
      • Figure 63: Data Table on Gene therapy - Year-over-year growth 2023-2028 (%)
    • 7.5 Market opportunity by Technology
      • Figure 64: Market opportunity by Technology ($ billion)
      • Figure 65: Data Table on Market opportunity by Technology ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Figure 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Figure 67: Chart on Market share by geography 2023-2028 (%)
      • Figure 68: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Figure 69: Chart on Geographic comparison
      • Figure 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Figure 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Figure 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Figure 73: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Figure 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Figure 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Figure 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Figure 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Figure 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Figure 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Figure 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Figure 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Figure 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Figure 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Figure 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Figure 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Figure 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Figure 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Figure 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Figure 89: Chart on US - Year-over-year growth 2023-2028 (%)
      • Figure 90: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Figure 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Figure 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Figure 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Figure 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 Japan - Market size and forecast 2023-2028
      • Figure 95: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
      • Figure 96: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
      • Figure 97: Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Figure 98: Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.10 UK - Market size and forecast 2023-2028
      • Figure 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Figure 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Figure 101: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Figure 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.11 China - Market size and forecast 2023-2028
      • Figure 103: Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Figure 104: Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Figure 105: Chart on China - Year-over-year growth 2023-2028 (%)
      • Figure 106: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Figure 107: Market opportunity by geography ($ billion)
      • Figure 108: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Figure 109: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Figure 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Figure 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Figure 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Figure 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Figure 114: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Figure 115: AbbVie Inc. - Overview
              • Figure 116: AbbVie Inc. - Product / Service
              • Figure 117: AbbVie Inc. - Key news
              • Figure 118: AbbVie Inc. - Key offerings
            • 12.4 Amgen Inc.
              • Figure 119: Amgen Inc. - Overview
              • Figure 120: Amgen Inc. - Product / Service
              • Figure 121: Amgen Inc. - Key offerings
            • 12.5 Baxter International Inc.
              • Figure 122: Baxter International Inc. - Overview
              • Figure 123: Baxter International Inc. - Business segments
              • Figure 124: Baxter International Inc. - Key news
              • Figure 125: Baxter International Inc. - Key offerings
              • Figure 126: Baxter International Inc. - Segment focus
            • 12.6 Becton Dickinson and Co.
              • Figure 127: Becton Dickinson and Co. - Overview
              • Figure 128: Becton Dickinson and Co. - Business segments
              • Figure 129: Becton Dickinson and Co. - Key news
              • Figure 130: Becton Dickinson and Co. - Key offerings
              • Figure 131: Becton Dickinson and Co. - Segment focus
            • 12.7 Cook Group Inc.
              • Figure 132: Cook Group Inc. - Overview
              • Figure 133: Cook Group Inc. - Product / Service
              • Figure 134: Cook Group Inc. - Key offerings
            • 12.8 Integra Lifesciences Corp.
              • Figure 135: Integra Lifesciences Corp. - Overview
              • Figure 136: Integra Lifesciences Corp. - Business segments
              • Figure 137: Integra Lifesciences Corp. - Key news
              • Figure 138: Integra Lifesciences Corp. - Key offerings
              • Figure 139: Integra Lifesciences Corp. - Segment focus
            • 12.9 Medtronic Plc
              • Figure 140: Medtronic Plc - Overview
              • Figure 141: Medtronic Plc - Business segments
              • Figure 142: Medtronic Plc - Key news
              • Figure 143: Medtronic Plc - Key offerings
              • Figure 144: Medtronic Plc - Segment focus
            • 12.10 Merck and Co. Inc.
              • Figure 145: Merck and Co. Inc. - Overview
              • Figure 146: Merck and Co. Inc. - Business segments
              • Figure 147: Merck and Co. Inc. - Key news
              • Figure 148: Merck and Co. Inc. - Key offerings
              • Figure 149: Merck and Co. Inc. - Segment focus
            • 12.11 MiMedx Group Inc.
              • Figure 150: MiMedx Group Inc. - Overview
              • Figure 151: MiMedx Group Inc. - Business segments
              • Figure 152: MiMedx Group Inc. - Key news
              • Figure 153: MiMedx Group Inc. - Key offerings
              • Figure 154: MiMedx Group Inc. - Segment focus
            • 12.12 Novartis AG
              • Figure 155: Novartis AG - Overview
              • Figure 156: Novartis AG - Business segments
              • Figure 157: Novartis AG - Key offerings
              • Figure 158: Novartis AG - Segment focus
            • 12.13 Nuvasive Inc.
              • Figure 159: Nuvasive Inc. - Overview
              • Figure 160: Nuvasive Inc. - Business segments
              • Figure 161: Nuvasive Inc. - Key news
              • Figure 162: Nuvasive Inc. - Key offerings
              • Figure 163: Nuvasive Inc. - Segment focus
            • 12.14 Organogenesis Holdings Inc.
              • Figure 164: Organogenesis Holdings Inc. - Overview
              • Figure 165: Organogenesis Holdings Inc. - Product / Service
              • Figure 166: Organogenesis Holdings Inc. - Key offerings
            • 12.15 Smith and Nephew plc
              • Figure 167: Smith and Nephew plc - Overview
              • Figure 168: Smith and Nephew plc - Business segments
              • Figure 169: Smith and Nephew plc - Key news
              • Figure 170: Smith and Nephew plc - Key offerings
              • Figure 171: Smith and Nephew plc - Segment focus
            • 12.16 Thermo Fisher Scientific Inc.
              • Figure 172: Thermo Fisher Scientific Inc. - Overview
              • Figure 173: Thermo Fisher Scientific Inc. - Business segments
              • Figure 174: Thermo Fisher Scientific Inc. - Key news
              • Figure 175: Thermo Fisher Scientific Inc. - Key offerings
              • Figure 176: Thermo Fisher Scientific Inc. - Segment focus
            • 12.17 Vericel Corp.
              • Figure 177: Vericel Corp. - Overview
              • Figure 178: Vericel Corp. - Product / Service
              • Figure 179: Vericel Corp. - Key news
              • Figure 180: Vericel Corp. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Figure 181: Inclusions checklist
                • Figure 182: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Figure 183: Currency conversion rates for US$
              • 13.4 Research methodology
                • Figure 184: Research methodology
                • Figure 185: Validation techniques employed for market sizing
                • Figure 186: Information sources
              • 13.5 List of abbreviations
                • Figure 187: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              regenerative medicine market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis